ARTICLE | Clinical News
EB-1020 SR: Phase IIa started
September 30, 2013 7:00 AM UTC
Neurovance began the single-blind, U.S. Phase IIa EB-1020-ADHD-201 trial to evaluate 300-500 mg EB-1020 SR daily for 4 weeks in about 40 adult male ADHD patients. ...